Glioma

Glioma spans IDH-mutant disease and glioblastoma (GBM), where EGFR alterations, TERT promoter, MGMT methylation, and DDR status shape therapy and prognosis. We provide antibodies for IDH1/2, ATRX, MGMT, and angiogenesis plus temozolomide, PARP, and MAPK probes for invasion, metabolism, and resistance.

Focus areas: MGMT & alkylator resistance, DDR defects, TAM/microglia, EGFRvIII & targeted delivery

Glioma-related antibodies (curated)

Loading…

Hot topics & directions

  • Temozolomide resistance: MGMT expression, MMR restoration, replication-stress readouts.
  • Immune-cold TME: Myeloid suppression, IDO/Arg axes, checkpoint combination limits.
  • Vascular mimicry & hypoxia: HIF programs and anti-angiogenic failure frameworks.
  • Tumor-treating fields (mechanism): Mitotic interference/DDR readouts in vitro (model-dependent).

Related targets

IDH / epigenetics
IDH1, IDH2, TET2, ATRX, histone H3 K27M (pediatric context)
RTK / MAPK
EGFR, EGFRvIII, MET, PDGFRA, MAPK1/3
Cell cycle / DDR
TP53, MDM2, CDKN2A/B, MGMT, PARP1, ATM, ATR
Angiogenesis / invasion
VEGFA, KDR, ANGPT2, MMP2/9, CHI3L1 (YKL-40)

Key signaling pathways

  1. RTK–RAS–PI3K
    Survival hub in GBM; EGFR lesions + PTEN loss bias signaling.
  2. DNA damage–cell cycle
    Couples TMZ/PARP strategies; checkpoint combinations need care.
  3. Hypoxia–HIF
    Perinecrotic gradients drive invasion and metabolism.
  4. Immune suppressive niche
    CSF1R/IDO axes in myeloid reprogramming (contextual).

Tool compounds (research use)

Commonly used for mechanistic studies; follow your lab SOP, compound datasheets, and ethics approvals.

CompoundTargets / pathwaysExperimental notes
TemozolomideDNA alkylation (MGMT-sensitive contexts)Serial readouts—pair MGMT with γH2AX.
VeliparibPARP1/2MGMT-low/HRD exploration; marrow suppression window.
OlaparibPARP1/2Synthetic lethality in DDR-defect models; sequence with RT carefully.
TrametinibMEK1/2MAPK probe in rare variants or RT combinations.
EverolimusmTORC1Survival programs in PTEN-loss contexts.
RegorafenibMulti-kinaseAngiogenesis + off-target kinases—matrix exposure/toxicity.
GSK2830371WIP1 (PPM1D)p53 stress-pathway tool (availability vendor-dependent).